Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Burger, J.; Tedeschi, A.; Barr, P.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Bartlett, N.; Li, Jianyong; Simpson, D.; Grosicki, S.; Devereux, S.; McCarthy, H.; Coutre, S.; Quach, H.; Gaidano, G.; Maslyak, Z.; Stevens, D.; Janssens, A.; Offner, F.; Mayer, J.; O'Dwyer, M.; Hellmann, A.; Schuh, A.; Siddiqi, T.; Polliack, A.; Tam, C.; Suri, Deepali; Cheng, M.; Clow, F.; Styles, L.; James, D.; Kipps, T.

doi:10.1056/NEJMoa1509388

Public

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

Shared by NobleBlocks on Dec 6, 2015 • 12:00 AM UTC

Authors:

J. Burger

A. Tedeschi

P. Barr

Abstract

BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlo...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!